Search Within

Linda Su Hyun Ahn

  1. "Epidemiology and Biostatistics"
Formats
  1. Journal Article (7)
  2. Meeting Abstract (2)
Groups
  1. Biostatistics Service (9)
  2. Department of Medicine (9)
  3. Epidemiology and Biostatistics (9)
  4. Nursing (9)
  5. Solid Tumor Oncology Division (9)
  6. Radiology, Department of (8)

More Groups

People
  1. Mark Kris (7)
  2. Ai Ni (6)
  3. Gregory Riely (5)
  4. Helena Yu (5)
  5. Rachel Kim (4)
  6. Robert Young (4)

More People

Years
  1. 2024 (1)
  2. 2023 (1)
  3. 2020 (2)
  4. 2019 (3)
  5. 2018 (1)
  6. 2017 (1)
Publications
  1. Journal of Clinical Oncology (2)
  2. Cancer (1)
  3. Clinical Cancer Research (1)
  4. Cold Spring Harbor Molecular Case Studies (1)
  5. JAMA Oncology (1)
  6. Journal of Thoracic Oncology (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (2)
  2. American Association for Cancer Research (1)
  3. American Medical Association (1)
  4. Cold Spring Harbor Laboratory Press (1)
  5. Elsevier Inc. (1)
  6. Elsevier Ireland Ltd. (1)

More Publishers

Results (9)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 2 study of amivantamab plus lazertinib in patients with EGFR-mutant lung cancer and active central nervous system disease
    Meeting Abstract

    Yu, H. A.; Chen, M. F.; Hui, A. B.; Choudhury, N. J.; Lee, J. J. K.; Zheng, J.; Ahn, L. S. H.; Pupo, A.; Nesselbush, M.; Jabara, I.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Targeting NFE2L2/KEAP1 mutations in advanced NSCLC with the TORC1/2 inhibitor TAK-228
    Journal Article

    Paik, P. K.; Fan, P. D.; Qeriqi, B.; Namakydoust, A.; Daly, B.; Ahn, L.; Kim, R.; Plodkowski, A.; Ni, A.; Chang, J.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Effect of osimertinib and bevacizumab on progression-free survival for patients with metastatic EGFR-mutant lung cancers: A phase 1/2 single-group open-label trial
    Journal Article

    Yu, H. A.; Schoenfeld, A. J.; Makhnin, A.; Kim, R.; Rizvi, H.; Tsui, D.; Falcon, C.; Houck-Loomis, B.; Meng, F.; Yang, J. L.; more...
    JAMA Oncology (2020)

    Fulltext@MSK | Save
  • A phase II trial of albumin-bound paclitaxel and gemcitabine in patients with newly diagnosed stage IV squamous cell lung cancers
    Journal Article

    Paik, P. K.; Kim, R. K.; Ahn, L.; Plodkowski, A. J.; Ni, A.; Donoghue, M. T. A.; Jonsson, P.; Villalona-Calero, M.; Ng, K.; McFarland, D.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • A phase 1/2 study of osimertinib and bevacizumab as initial treatment for patients with metastatic EGFR-mutant lung cancers
    Meeting Abstract

    Yu, H. A.; Kim, R.; Makhnin, A.; Ahn, L. S. H.; Ni, A.; Hayes, S. A.; Young, R. J.; Riely, G. J.; Kris, M. G.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A phase II trial of sorafenib and dacarbazine for leiomyosarcoma, synovial sarcoma, and malignant peripheral nerve sheath tumors
    Journal Article

    D'Adamo, D. R.; Dickson, M. A.; Keohan, M. L.; Carvajal, R. D.; Hensley, M. L.; Hirst, C. M.; Ezeoke, M. O.; Ahn, L.; Qin, L. X.; Antonescu, C. R.; more...
    The Oncologist (2019)

    Fulltext@MSK | Save
  • Exceptional responders with invasive mucinous adenocarcinomas: A phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers
    Journal Article

    Drilon, A.; Schoenfeld, A. J.; Arbour, K. C.; Litvak, A.; Ni, A.; Montecalvo, J.; Yu, H. A.; Panora, E.; Ahn, L.; Kennedy, M.; more...
    Cold Spring Harbor Molecular Case Studies (2019)

    Fulltext@MSK | Save
  • Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor–mutant lung cancers and brain metastases
    Journal Article

    Arbour, K. C.; Kris, M. G.; Riely, G. J.; Ni, A.; Beal, K.; Daras, M.; Hayes, S. A.; Young, R. J.; Rodriguez, C. R.; Ahn, L.; more...
    Cancer (2018)

    Fulltext@MSK | Save
  • Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas
    Journal Article

    Schilsky, J. B.; Ni, A.; Ahn, L.; Datta, S.; Travis, W. D.; Kris, M. G.; Chaft, J. E.; Rekhtman, N.; Hellmann, M. D.
    Lung Cancer (2017)

    Fulltext@MSK | Save